Compounds for inducing anti-tumor immunity and methods thereof
US-2016237429-A1 · Aug 18, 2016 · US
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
US9956236B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9956236-B2 |
| Application number | US-201213983180-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 7, 2012 |
| Priority date | Feb 7, 2011 |
| Publication date | May 1, 2018 |
| Grant date | May 1, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides, e.g., compositions and methods for increasing activation of immune cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for increasing activation of immune cells in a subject, comprising administering at least one toll-like receptor (TLR) agonist and a human immunodeficiency virus (HIV) protease inhibitor that activates IRE-1 in the subject thereby increasing activation of immune cells in the subject, wherein the toll-like receptor (TLR) agonist stimulates TLR4; and contacting the immune cells with an antigen to which an immune response is desired. 2. The method of claim 1 , wherein the subject has cancer. 3. The method of claim 1 , wherein production of a proinflammatory cytokine by the immune cells is increased. 4. The method of claim 3 , wherein the proinflammatory cytokine is interleukin-6 (IL-6). 5. The method of claim 1 , wherein the expression of at least one costimulatory molecule is increased. 6. The method of claim 5 , wherein the expression of cluster of differentiation 40 (CD40) is increased. 7. The method of claim 1 , wherein the immune cells comprise macrophages. 8. The method of claim 1 , wherein the HIV protease inhibitor is selected from the group consisting of: Atazanavir, Lopinavir, Nelfinavir and Ritonavir. 9. The method of claim 8 , wherein the HIV protease inhibitor is Nelfinavir. 10. The method of claim 1 , wherein the activation of immune cells is increased in vivo.
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings · CPC title
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Non-condensed isoquinolines, e.g. papaverine · CPC title
- A61K31/675Primary
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9956236B2 cover?
- The invention provides, e.g., compositions and methods for increasing activation of immune cells.
- Who is the assignee on this patent?
- Glimcher Laurie H, Bettigole Sarah, Martinon Fabio, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/675. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).